Illumina is trading 4.22% up at $239.75, extending its recent rally as investors position for S&P 500 inclusion before the September 21, 2026 open.
- Index-tracking funds may need to purchase shares, creating anticipated institutional demand.
- The broader risk-on session and biotech strength are providing additional support.
- UBS’s September 9 Buy upgrade and $260 target reinforce bullish sentiment.